SecProbe.io

Filing text and metadata
Intelligence Terminal Search Topics Monthly Activity About

UPLOAD Filing

Vireo Growth Inc.
Date: July 18, 2025 · CIK: 0001771706 · Accession: 0000000000-25-007628

Regulatory Compliance Offering / Registration Process

AI Filing Summary & Sentiment

Sentiment
Urgency
Document Type
Confidence
SEC Posture
Company Posture

Summary

Reasoning

File numbers found in text: 333-288686

Date
July 18, 2025
Author
Division of
Form
UPLOAD
Company
Vireo Growth Inc.

Letter

Re: Vireo Growth Inc. Registration Statement on Form S-3 Filed July 15, 2025 File No. 333-288686 Dear John Mazarakis:

July 18, 2025

John Mazarakis Chief Executive Officer Vireo Growth Inc. 209 South 9th Street Minneapolis, MN 55402

This is to advise you that we have not reviewed and will not review your registration statement.

Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Please contact Lauren Hamill at 303-844-1008 with any questions.

Sincerely,
Division of
Corporation Finance
Office of Life
Sciences
cc: Alexander Yarbrough

Show Raw Text
<DOCUMENT>
<TYPE>TEXT-EXTRACT
<SEQUENCE>2
<FILENAME>filename2.txt
<TEXT>
 July 18, 2025

John Mazarakis
Chief Executive Officer
Vireo Growth Inc.
209 South 9th Street
Minneapolis, MN 55402

 Re: Vireo Growth Inc.
 Registration Statement on Form S-3
 Filed July 15, 2025
 File No. 333-288686
Dear John Mazarakis:

 This is to advise you that we have not reviewed and will not review your
registration
statement.

 Please refer to Rules 460 and 461 regarding requests for acceleration.
We remind you
that the company and its management are responsible for the accuracy and
adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action
by the staff.

 Please contact Lauren Hamill at 303-844-1008 with any questions.

 Sincerely,

 Division of
Corporation Finance
 Office of Life
Sciences
cc: Alexander Yarbrough
</TEXT>
</DOCUMENT>